ArticleFrontiers in oncology2019
Everolimus in Anaplastic Thyroid Cancer: A Case Series.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- [Update on anaplastic thyroid cancer-What is relevant for surgeons?]Chirurgie (Heidelberg, Germany) · 2025Guideline
- Anaplastic thyroid cancer: genomic landscape, molecular drivers and novel therapeutics.Nature reviews. Endocrinology · 2026Review
- Cancer Stemness and Dedifferentiation in Anaplastic Thyroid Carcinoma: Insights into a Multigenic, Microenvironmental Network and the Role of CD44.Biomedicines · 2026Review
- Overlap MCAP-CLAPO syndrome associated with malignant ovarian tumor in a 11 year old girl.JAAD case reports · 2026Article
- Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.Genes & diseases · 2025Review
- Review
- [Personalized approach to anaplastic thyroid carcinoma].Chirurgie (Heidelberg, Germany) · 2024Review
- First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.BMC endocrine disorders · 2024Article
- Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Review
- Review
- Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer.Frontiers in endocrinology · 2022Review
- Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects.Journal of endocrinological investigation · 2021Review
- Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.Thyroid : official journal of the American Thyroid Association · 2021Article
- PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.Oncology letters · 2021Article
- Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs.Cancers · 2021Review
- Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.Current oncology reports · 2021Review
- Recent advances in the management of anaplastic thyroid cancer.Thyroid research · 2020Review
- Molecular Markers Guiding Thyroid Cancer Management.Cancers · 2020Review
- Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.